Aqualung Therapeutics has developed a first in man novel humanized monoclonal antibody (mAb eNamptor) targeting inflammation. We intend to treat conditions such as Acute Respiratory Distress Syndrome,Prostate Cancer and Chorioamnionitis (which leads to premature birth.)